Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of BMS-986259 (FA-Relaxin) in Stabilized Patients Hospitalized for Acute Decompensated Heart Failure
2019-004186-40Phase 2Unknown
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure (HF) comparing BMS-986259 with Placebo (2 arms). Primary endpoint: Incidence of clinically relevant hypotension. Status: unknown.
02
Drugs
FA relaxin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on 2019-004186-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004186-40.